[1] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut, 2021,70(5):962-969.
[2] Sinn DH, Kang D, Cho SJ, et al. Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. Eur J Endocrinol, 2019,181(2):185-192.
[3] Li B, Zhang C, Zhan YT. Nonalcoholic fatty liver disease cirrhosis: a review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis. Can J Gastroenterol Hepatol, 2018,2018(6):2784537.
[4] Hu Y, Shi R, Mo R, et al. Nomogram for the prediction of diabetic nephropathy risk among patients with type 2 diabetes mellitus based on a questionnaire and biochemical indicators: a retrospective study. Aging (Albany NY), 2020,12(11):10317-10336.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[6] Xia S, Ren X, Ni Z, et al. A noninvasive method——shear-wave elastography compared with transient elastography in evaluation of liver fibrosis in patients with chronic hepatitis B. Ultrasound Q, 2019,35(2):147-152.
[7] 中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版). 中华内分泌代谢杂志, 2018,34(7):549-554.
[8] Hameed EK. Tyg index a promising biomarker for glycemic control in type 2 diabetes mellitus. Diabetes Metab Syndr, 2019,13(1):560-563.
[9] Tada T, Toyoda H, Sone Y, et al. Type 2 diabetes mellitus: a risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol, 2019,34(11):2011-2018.
[10] Cusi K, Sanyal AJ, Zhang S, et al. Non-alcoholic fatty liver disease (nafld) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab, 2017,19(11):1630-1634.
[11] Kim K, Oh TJ, Cho HC, et al. Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes. Sci Rep, 2021,11(1):24372.
[12] Huang J, Li R, Liu N, et al. Liver fibrosis is independently associated with diabetic peripheral neuropathy in type 2 diabetes mellitus. J Diabetes Investig, 2021,12(11):2019-2027.
[13] Greco C, Nascimbeni F, Carubbi F, et al. Association of nonalcoholic fatty liver disease (nafld) with peripheral diabetic polyneuropathy: a systematic review and meta-analysis. J Clin Med, 2021,10(19):4466.
[14] Mirr M, Skrypnik D, Bogdański P, et al. Newly proposed insulin resistance indexes called tyg-nc and tyg-nhtr show efficacy in diagnosing the metabolic syndrome. J Endocrinol Invest, 2021,44(12):2831-2843.
[15] Paschalis P, Athyros Vasilios G, Achilleas T, et al. Can serum uric acid lowering therapy contribute to the prevention or treatment of nonalcoholic fatty liver disease? Curr Vasc Pharmacol, 2018,16(3):269-275.
[16] Sandra S, Lesmana C, Purnamasari D, et al. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (nafld) progression evaluated using controlled attenuation parameter-transient elastography: lesson learnt from tertiary referral center. Diabetes Metab Syndr, 2019,13(1):424-428.
[17] Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol, 2022,10(4):284-296.
[18] Manilla V, Santopaolo F, Gasbarrini A, Ponziani FR.Type 2 Diabetes Mellitus and Liver Disease: Across the Gut-Liver Axis from Fibrosis to Cancer. Nutrients, 2023,15(11):2521.
[19] Jorge A, Andrade J, Paraíso AF, et al. Body mass index and the visceral adipose tissue expression of il-6 and tnf-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class iii obesity. Obes Res Clin Pract, 2018,12(2):1-8.
[20] Milaciu MV, Ciumărnean L, Matei DM, et al. Cytokines, paraoxonase-1, periostin and non-invasive liver fibrosis scores in patients with non-alcoholic fatty liver disease and persistently elevated aminotransferases: a pilot study. Exp Ther Med, 2021,21(5):533. |